Interferon α may be back on track to treat acute myeloid leukemia

Abstract

Our own experience and a thorough literature review suggest that interferon α (IFNα) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFNα for several months, which can be obtained by using pegylated IFNα. © 2013 Landes Bioscience.